← Back to All US Stocks

Opthea Ltd (OPTEY) Fundamental Analysis & AI Grade 2026

OPTEY OTC Biological Products, (No Diagnostic Substances) C3 CIK: 0001815620
Recently Updated • Analysis: Jul 13, 2026 • SEC Data: 2026-07-13

Opthea Ltd (OPTEY) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

OPTEY Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

OPTEY vs Healthcare Sector: How Opthea Ltd Compares

How Opthea Ltd compares to Healthcare sector averages

Net Margin
OPTEY 0.0%
vs
Sector Avg 12.0%
OPTEY Sector
ROE
OPTEY 0.0%
vs
Sector Avg 15.0%
OPTEY Sector
Current Ratio
OPTEY 0.0x
vs
Sector Avg 2.0x
OPTEY Sector
Debt/Equity
OPTEY 0.0x
vs
Sector Avg 0.6x
OPTEY Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Opthea Ltd Stock Overvalued? OPTEY Valuation Analysis 2026

Based on fundamental analysis, Opthea Ltd has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Opthea Ltd Balance Sheet: OPTEY Debt, Cash & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

OPTEY Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

OPTEY SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Opthea Ltd (CIK: 0001815620)

📋 Recent SEC Filings

Date Form Document Action
Feb 16, 2021 SC 13G tm214392d11_sc13g.htm View →
Nov 12, 2020 SC 13G r1110202sc13g.htm View →

Frequently Asked Questions about OPTEY

What is the AI rating for OPTEY?

Opthea Ltd (OPTEY) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.

What are OPTEY's key strengths?

Claude: Analysis in progress.

What are the risks of investing in OPTEY?

Claude: Analysis in progress.

What is OPTEY's revenue and growth?

Opthea Ltd reported revenue of N/A.

Does OPTEY pay dividends?

Opthea Ltd does not currently pay dividends.

Where can I find OPTEY SEC filings?

Official SEC filings for Opthea Ltd (CIK: 0001815620) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is OPTEY's EPS?

Opthea Ltd has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is OPTEY's fundamental grade?

Based on our AI fundamental analysis in July 2026, Opthea Ltd has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is OPTEY stock overvalued or undervalued?

Valuation metrics for OPTEY: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is OPTEY's AI grade for 2026?

Our dual AI analysis gives Opthea Ltd a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is OPTEY's free cash flow?

Opthea Ltd's operating cash flow is N/A, with capital expenditures of N/A.

How does OPTEY compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% CRDO 87% AVGO 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Jul 13, 2026 | Data as of: 2026-07-13 | Powered by Claude AI